Vaxcyte Stock Jumps 30.7% After Positive VAX-31 Pneumococcal Vaccine Data
Vaxcyte shares surged 30.70% after positive Phase 2 data for VAX-31, highlighting the volatility of clinical-stage biotech catalysts.
AbbVie Adds Two FDA Breakthrough Designations as Temab-A Builds Pipeline Momentum
AbbVie’s Temab-A earned two FDA breakthrough designations, adding an oncology catalyst alongside JUV…
Lipocine Stock Jumps 30% on Health Canada Approval for TLANDO
LPCN’s 30% jump adds regulatory, commercial and clinical catalysts to a biotech trading setup focuse…
Vaxcyte Stock Jumps 30.7% on Positive VAX-31 Pneumococcal Vaccine Data
Vaxcyte’s $PCVX stock jumped 30.70% after positive VAX-31 data, putting vaccine developers back in t…
ArriVent BioPharma Stock Plunges 63% After Lung Cancer Drug Misses Phase 3 Endpoint
ArriVent BioPharma shares fell 63% after its Phase 3 FURVENT trial missed its primary endpoint, high…
Option Care Health Surges 34% as McKesson and CD&R Agree to $5.8 Billion Takeover
Option Care Health jumped 34% after McKesson and CD&R agreed to a $5.8 billion takeover, highlightin…
ArriVent’s AVBP Plunges 60% After Lung Cancer Trial Misses Primary Endpoint
ArriVent shares plunged 60% after its lung-cancer trial missed the primary endpoint, despite dose-de…
BridgeBio’s $BBIO Gains FDA Priority Review for Oral Infigratinib in Children With Achondroplasia
BridgeBio’s NDA for oral infigratinib received FDA acceptance and Priority Review, creating a closel…
Cenovus to Acquire Athabasca Oil in $5.7 Billion Cash-and-Stock Deal
Cenovus will acquire Athabasca Oil in a $5.7 billion cash-and-stock transaction, marking a major ste…
Vaxcyte Hits 52-Week High as Phase 3 Data Boosts VAX-31 Prospects
Vaxcyte reached a new 52-week high after positive topline Phase 3 OPUS-1 results strengthened the ca…